Vimarsana
Biggest News Aggregation in the World

Page 42 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guide Today - Breaking & Trending Today

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma - Vimarsana News

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, ...

Stock Market | FinancialContent Business Page - Vimarsana News

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress - Vimarsana News

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across... | June 11, 2023

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) injection - Vimarsana News

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) injection

/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today a partnership with Applied Radiology,...

Corium's Novel ADHD Medication AZSTARYS® (Serdexmethylphenidate and Dexmethylphenidate) Had No Clinically Significant Impact on Children's Weight and Height Growth Rate - Vimarsana News

Corium's Novel ADHD Medication AZSTARYS® (Serdexmethylphenidate and Dexmethylphenidate) Had No Clinically Significant Impact on Children's Weight and Height Growth Rate

/PRNewswire/ -- Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS)...